AMS - Ticker AI Digest

Advanced Medical Solutions Group plc 📰 1
TradingFloor AI GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Advanced Medical Solutions Group plc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, crunch, and the deeper desks.
AMS Data 2026-03-18 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (AMS) 1
AMS 06:01
Advanced Medical Solutions Group plc
Unaudited Preliminary Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Advanced Medical Solutions Group plc (AMS) reported unaudited preliminary results for the year ended 31 December 2025, highlighting record full-year sales and adjusted EBITDA with strong organic growth. Key financial and operational highlights include
**Revenue Growth**Total Group revenue increased by 29% to £228.9 million, driven by the full-year impact of the Peters Surgical acquisition and continued growth across key product categories. The Surgical Business Unit saw a 36% increase in revenue to £183.5 million, while the Advanced Woundcare Business Unit grew by 9% to £45.4 million.
**Adjusted EBITDA**Increased by 24% to £49.9 million, reflecting strong profitability and operational performance.
**Net Debt Reduction**Net debt decreased to £50.5 million from £55.8 million in 2024, despite significant investment in transformation projects.
**Dividend Increase**The proposed full-year dividend per share increased by 10% to 2.86p.
**Integration Progress**Successful integration of Peters Surgical and Syntacoll, with commercial synergies already contributing to growth and operational synergies on track.
**Innovation Pipeline**Multiple product approvals expected from 2026 onwards, supporting long-term growth.
**Outlook**AMS expects continued strong growth in Surgical and modest growth in Woundcare, with strong cash generation supporting deleveraging and investment in innovation.
The Board is confident in delivering 2026 revenue and EBITDA in line with market expectations, positioning AMS for sustained growth and long-term value creation.
Here is the comparison of financials and debt year on year in an HTML table format:
Financial Metric2024 (£ million)2025 (£ million)Change (£ million)Change (%)
Total Group Revenue177.5228.951.429%
Adjusted EBITDA40.249.99.724%
Adjusted Profit Before Tax29.433.94.515%
Profit Before Tax9.817.88.081%
Net Operating Cash Flow19.532.613.167%
Net (Debt)/Cash(55.8)(50.5)5.3-10%

Debt Comparison

Debt Metric2024 (£ million)2025 (£ million)Change (£ million)
Net Debt(55.8)(50.5)5.3
Facility A Borrowings(59.5)(54.8)4.7
Facility B Borrowings(11.9)(6.0)5.9
Other Debt(1.4)(7.0)(5.6)
**Key Observations:** * **Revenue Growth:** Total Group Revenue increased by 29% from £177.5 million in 2024 to £228.9 million in 2025. * **Profitability Improvement:** Adjusted EBITDA and Adjusted Profit Before Tax increased by 24% and 15%, respectively, indicating improved operational efficiency. * **Debt Reduction:** Net Debt decreased by £5.3 million from £(55.8) million in 2024 to £(50.5) million in 2025, primarily due to reduced borrowings under Facility A and Facility B. * **Cash Flow Improvement:** Net Operating Cash Flow increased significantly by 67% from £19.5 million in 2024 to £32.6 million in 2025, reflecting improved cash generation. Note: The percentage change for Net (Debt)/Cash is calculated as a decrease in absolute terms, hence the negative sign.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
AMS 06:01
Advanced Medical Solutions Group plc
Unaudited Preliminary Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Advanced Medical Solutions Group plc (AMS) reported unaudited preliminary results for the year ended 31 December 2025, highlighting record full-year sales and adjusted EBITDA with strong organic growth. Key financial and operational highlights include
**Revenue Growth**Total Group revenue increased by 29% to £228.9 million, driven by the full-year impact of the Peters Surgical acquisition and continued growth across key product categories. The Surgical Business Unit saw a 36% increase in revenue to £183.5 million, while the Advanced Woundcare Business Unit grew by 9% to £45.4 million.
**Adjusted EBITDA**Increased by 24% to £49.9 million, reflecting strong profitability and operational performance.
**Net Debt Reduction**Net debt decreased to £50.5 million from £55.8 million in 2024, despite significant investment in transformation projects.
**Dividend Increase**The proposed full-year dividend per share increased by 10% to 2.86p.
**Integration Progress**Successful integration of Peters Surgical and Syntacoll, with commercial synergies already contributing to growth and operational synergies on track.
**Innovation Pipeline**Multiple product approvals expected from 2026 onwards, supporting long-term growth.
**Outlook**AMS expects continued strong growth in Surgical and modest growth in Woundcare, with strong cash generation supporting deleveraging and investment in innovation.
The Board is confident in delivering 2026 revenue and EBITDA in line with market expectations, positioning AMS for sustained growth and long-term value creation.
Here is the comparison of financials and debt year on year in an HTML table format:
Financial Metric2024 (£ million)2025 (£ million)Change (£ million)Change (%)
Total Group Revenue177.5228.951.429%
Adjusted EBITDA40.249.99.724%
Adjusted Profit Before Tax29.433.94.515%
Profit Before Tax9.817.88.081%
Net Operating Cash Flow19.532.613.167%
Net (Debt)/Cash(55.8)(50.5)5.3-10%

Debt Comparison

Debt Metric2024 (£ million)2025 (£ million)Change (£ million)
Net Debt(55.8)(50.5)5.3
Facility A Borrowings(59.5)(54.8)4.7
Facility B Borrowings(11.9)(6.0)5.9
Other Debt(1.4)(7.0)(5.6)
**Key Observations:** * **Revenue Growth:** Total Group Revenue increased by 29% from £177.5 million in 2024 to £228.9 million in 2025. * **Profitability Improvement:** Adjusted EBITDA and Adjusted Profit Before Tax increased by 24% and 15%, respectively, indicating improved operational efficiency. * **Debt Reduction:** Net Debt decreased by £5.3 million from £(55.8) million in 2024 to £(50.5) million in 2025, primarily due to reduced borrowings under Facility A and Facility B. * **Cash Flow Improvement:** Net Operating Cash Flow increased significantly by 67% from £19.5 million in 2024 to £32.6 million in 2025, reflecting improved cash generation. Note: The percentage change for Net (Debt)/Cash is calculated as a decrease in absolute terms, hence the negative sign.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
AMS 13:28
Advanced Medical Solutions Group plc
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 4
AMS 06:01
Advanced Medical Solutions Group plc
Unaudited Preliminary Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Advanced Medical Solutions Group plc (AMS) reported unaudited preliminary results for the year ended 31 December 2025, highlighting record full-year sales and adjusted EBITDA with strong organic growth. Key financial and operational highlights include
**Revenue Growth**Total Group revenue increased by 29% to £228.9 million, driven by the full-year impact of the Peters Surgical acquisition and continued growth across key product categories. The Surgical Business Unit saw a 36% increase in revenue to £183.5 million, while the Advanced Woundcare Business Unit grew by 9% to £45.4 million.
**Adjusted EBITDA**Increased by 24% to £49.9 million, reflecting strong profitability and operational performance.
**Net Debt Reduction**Net debt decreased to £50.5 million from £55.8 million in 2024, despite significant investment in transformation projects.
**Dividend Increase**The proposed full-year dividend per share increased by 10% to 2.86p.
**Integration Progress**Successful integration of Peters Surgical and Syntacoll, with commercial synergies already contributing to growth and operational synergies on track.
**Innovation Pipeline**Multiple product approvals expected from 2026 onwards, supporting long-term growth.
**Outlook**AMS expects continued strong growth in Surgical and modest growth in Woundcare, with strong cash generation supporting deleveraging and investment in innovation.
The Board is confident in delivering 2026 revenue and EBITDA in line with market expectations, positioning AMS for sustained growth and long-term value creation.
Here is the comparison of financials and debt year on year in an HTML table format:
Financial Metric2024 (£ million)2025 (£ million)Change (£ million)Change (%)
Total Group Revenue177.5228.951.429%
Adjusted EBITDA40.249.99.724%
Adjusted Profit Before Tax29.433.94.515%
Profit Before Tax9.817.88.081%
Net Operating Cash Flow19.532.613.167%
Net (Debt)/Cash(55.8)(50.5)5.3-10%

Debt Comparison

Debt Metric2024 (£ million)2025 (£ million)Change (£ million)
Net Debt(55.8)(50.5)5.3
Facility A Borrowings(59.5)(54.8)4.7
Facility B Borrowings(11.9)(6.0)5.9
Other Debt(1.4)(7.0)(5.6)
**Key Observations:** * **Revenue Growth:** Total Group Revenue increased by 29% from £177.5 million in 2024 to £228.9 million in 2025. * **Profitability Improvement:** Adjusted EBITDA and Adjusted Profit Before Tax increased by 24% and 15%, respectively, indicating improved operational efficiency. * **Debt Reduction:** Net Debt decreased by £5.3 million from £(55.8) million in 2024 to £(50.5) million in 2025, primarily due to reduced borrowings under Facility A and Facility B. * **Cash Flow Improvement:** Net Operating Cash Flow increased significantly by 67% from £19.5 million in 2024 to £32.6 million in 2025, reflecting improved cash generation. Note: The percentage change for Net (Debt)/Cash is calculated as a decrease in absolute terms, hence the negative sign.
AMS 13:28
Advanced Medical Solutions Group plc
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
AMS 06:01
Advanced Medical Solutions Group plc
Block listing Interim Review
AMS 08:01
Advanced Medical Solutions Group plc
Total Voting Rights

AI Crunch

Single-Ticker AI Crunch
AMS signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Advanced Medical Solutions Group plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AMS AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for AMS on 2026-03-18.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
493.4M
Enterprise Value
530.9M
Public Float
77.1
Broker Target
275.625
Shares Out
216.4M
Long Interest
100
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
GB0004536594
Market
LSE - AIM
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for AMS.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-03-18 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
Advanced Medical Solutions Group plc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
0.03
Ex Divi
2026-05-28
Earnings Date
2026-03-18
Net Debt
63.5M
Cash
18.0M
EPS
0.05
Net Income
10.0M
Revenue
228.9M
Enterprise Value
530.9M
Trailing PE
45.6
Forward PE
19.7239
Price Sales TTM
2.1552
Price Book MRQ
1.9066
EV Revenue
2.4326
EV EBITDA
12.5798
Financial Forecastist

Improving financial engine

Revenue is accelerating +87.2% against the prior comparable period. Net margin is compressing by 7.8 pts. Net debt is coming down +224.5%.

Revenue +87.2% Net Income -46.1% FCF +70.7% Current Ratio 2.79x Forward Rev 0
Improving
Quarter Revenue
118.2M
+87.2%
vs prior comparable quarter
Net Margin
+3.2%
-7.8 pts
profitability pulse
Free Cash Flow
11.0M
+70.7%
cash conversion
Net Debt / EBITDA
2.8x
-224.5%
lower is cleaner
Revenue Engine

Latest quarter printed 118.2M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at 3.7M and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 18.0M while net debt is 63.5M. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q2 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
246.0M
Revenue Path
0.13
EPS / Earnings
Growth cue +0.1%
FY 2027
Consensus
264.0M
Revenue Path
0.16
EPS / Earnings
Growth cue +0.3%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 118.2M 3.7M 11.0M 63.5M
Q2 2025 110.8M 6.2M 12.8M 63.0M
Q4 2024 109.5M 3.0M 6.4M 72.6M
Q2 2024 68.0M 4.2M 5.4M -45.1M
Q4 2023 63.1M 7.0M 6.4M -51.0M
Q2 2023 63.1M 8.9M 281.0K -60.0M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 228.9M 10.0M 43.4M 21.4M
FY 2024 177.5M 7.1M 29.7M 12.7M
FY 2023 126.2M 15.9M 31.4M 2.5M
FY 2022 124.3M 20.4M 34.9M 16.9M
FY 2021 108.6M 17.5M 31.5M 24.6M

Structure DNA

Market Structure DNA has not been loaded for this ticker yet. Once the A15 loader runs, this desk will light up with regime labels, ownership lock, dividend cadence, and structure charts.

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
20.6688
Institutions As Of
2026-04-08
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
2
Sale Director Dealing
3
Purchase TR1
5
Sale TR1
6
Broker Coverage Rows
1
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for AMS, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-03-18 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
Advanced Medical Solutions Group plc has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
AMS Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-03-18 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 13.41%
RSI Gauge
Price Change
AI Forecast